Quirine V. R.
- Country
- The Netherlands
- Department
- Oncology
Research Overview
- Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy
- Phase 3 Randomized Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in HR+/HER2- Metastatic Breast Cancer
- Evaluation of Image-Guided De-Escalation of Neoadjuvant Chemotherapy with Trastuzumab, Pertuzumab, and Drug Combination in HER2-Positive Breast Cancer
Data & Insights
Has run more than one trial at 78 of 215 partner sites.
Specializations
Breast Cancer Treatment Innovation
Specializes in developing therapeutic approaches for hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular focus on investigating novel combination therapies including PIK3CA mutation-targeted treatments.
- Advanced metastatic breast cancer interventions
- Triple-negative breast cancer therapy
- HER2-positive treatment optimization
Explores targeted therapies involving CDK4/6 inhibition and endocrine therapy combinations.
Oncology Specializations
Conducts research in multiple cancer types, including renal cell carcinoma and follicular lymphoma, with emphasis on immunotherapy approaches and targeted treatments.
- Prostate cancer management
- Advanced therapeutic combinations
- Biomarker-driven treatment strategies
Focuses on developing personalized treatment approaches based on specific genetic and molecular markers.
Clinical Innovation
Leads investigations in image-guided therapy optimization and chemotherapy de-escalation strategies, particularly in breast cancer treatment protocols.
- Neoadjuvant therapy approaches
- Treatment sequencing studies
- Long-term safety assessments
Investigates novel therapeutic combinations to improve patient outcomes in advanced cancer settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.